NDLI: Systematic reviews of assessment measures and pharmacologic treatments for agitation.

Please wait, while we are loading the content...

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.

Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.

Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study.

Anaphylactoid reaction considered ciprofloxacin related: a case report and literature review.

Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.

Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.

Health care reform in the United States: so near and yet so far.

Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.

Mycophenolate mofetil 500-mg tablet under fasting conditions: single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects.

Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.

Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.

Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers.

Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.

Year: 2010 Volume: 32 Issue: 2

Year: 2010 Volume: 32 Issue: Supplementary 2

Year: 2010 Volume: 32 Issue: 1

Year: 2010 Volume: 32 Issue: Supplementary 1

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

Systematic reviews of assessment measures and pharmacologic treatments for agitation.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Zeller, Scott L. Rhoades, Robert W.
Description	Country affiliation: United States Author Affiliation: Zeller SL ( Alameda County Medical Center, Oakland, California 94602, USA. szellermd@gmail.com)
Abstract	BACKGROUND: Agitation is a common behavioral emergency associated with high risk of injury to patients and health care professionals. There are a wide variety of approaches to assessing the severity of agitation and the risk of violence/aggression, and many different pharmacotherapies have been used to manage this condition. OBJECTIVES: Two systematic reviews were carried out. The first focused on measures used to assess agitation and predict aggression/violence and/or the need for medication. The second focused on clinical trials of the efficacy and tolerability of pharmacotherapies for agitation. METHODS: Publications relevant to each topic were identified by searches of MEDLINE through December 24, 2009. The search concerning the assessment of agitation included the terms agitation AND assessment AND (scale OR instrument); the search for clinical trials of pharmacotherapies for agitation included the terms agitation and treatment AND (emergency OR acute). Both searches were limited to reports of studies published in English involving patients aged > or =18 years. RESULTS: The literature search identified 13 scales used to assess the severity of agitation across multiple patient populations; only 3 of these reports involved the prediction of aggression/violence in patients with agitation, and 1 involved prediction of the need for medication. Thirty-one clinical trials of pharmacotherapy for agitation were identified by the literature search. Based on their results, orally administered olanzapine, risperidone, aripiprazole, quetiapine, haloperidol, and lorazepam; intramuscularly administered olanzapine, lorazepam, ziprasidone, haloperidol, aripiprazole, midazolam, and droperidol; and intravenously administered droperidol and lorazepam were effective for the treatment of agitation. The intramuscular route of administration was associated with a more rapid onset of action compared with the oral route (eg, for olanzapine, 30 minutes vs 1 hour, respectively). CONCLUSIONS: Agitation is a common behavioral emergency that may require pharmacotherapy. The management of agitated patients may be improved through the use of easy-to-administer instruments that predict the need for medication and the availability of rapid-acting treatments that are well accepted by patients and health care professionals.
File Format	HTM / HTML
ISSN	01492918
Issue Number	3
Volume Number	32
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2010-03-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Aggression Drug Effects Antipsychotic Agents Therapeutic Use Violence Psychology Anti-anxiety Agents Administration & Dosage Adverse Effects Clinical Trials As Topic Humans Lorazepam Severity Of Illness Index Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Chlorpromazine for psychosis-induced aggression or agitation.

Ciclesonide and the treatment of asthma.

Models for event-driven data: longitudinal daily adverse event and dropout.

Drug safety evaluation of apremilast for treating psoriatic arthritis.

Valbenazine granted breakthrough drug status for treating tardive dyskinesia.

Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.

'First do no harm.' A systematic review of the prevalence and management of antipsychotic adverse effects.

Cyproterone to treat aggressivity in dementia: a clinical case and systematic review.

Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.

Systematic reviews of assessment measures and pharmacologic treatments for agitation.

Similar Documents

Chlorpromazine for psychosis-induced aggression or agitation.

Ciclesonide and the treatment of asthma.

Models for event-driven data: longitudinal daily adverse event and dropout.

Drug safety evaluation of apremilast for treating psoriatic arthritis.

Valbenazine granted breakthrough drug status for treating tardive dyskinesia.

Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.

'First do no harm.' A systematic review of the prevalence and management of antipsychotic adverse effects.

Cyproterone to treat aggressivity in dementia: a clinical case and systematic review.

Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.

Systematic reviews of assessment measures and pharmacologic treatments for agitation.